XML 58 R49.htm IDEA: XBRL DOCUMENT v3.25.1
Other Significant Agreements - Paragon Agreement (Details)
1 Months Ended 3 Months Ended
Aug. 12, 2024
USD ($)
Nov. 30, 2023
USD ($)
Nov. 30, 2022
USD ($)
Item
shares
Mar. 31, 2025
USD ($)
shares
Dec. 31, 2024
USD ($)
shares
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Other Significant Agreements Paragon Option Agreement                  
Research and development [1]       $ 46,387,000       $ 28,716,000  
Issued total common units (in shares) | shares       59,526,170 59,478,725        
Option Agreement                  
Other Significant Agreements Paragon Option Agreement                  
Payments due upon exercise of option   $ 0              
Paragon IL13 License Agreement | Related party                  
Other Significant Agreements Paragon Option Agreement                  
Nomination fee paid                 $ 2,000,000
Paragon Therapeutics, Inc | Related party                  
Other Significant Agreements Paragon Option Agreement                  
Research and development               6,500,000  
Paragon Therapeutics, Inc | Option Agreement                  
Other Significant Agreements Paragon Option Agreement                  
Payments due upon exercise of option     $ 0            
Termination period of agreement   30 days 30 days            
Period of material breach   30 days 30 days            
Threshold number of days for termination upon failure to make payment and such failure persists even after the notice   30 days 30 days            
Payment of non-refundable fees               2,000,000  
Paragon Therapeutics, Inc | Option Agreement | Related party                  
Other Significant Agreements Paragon Option Agreement                  
Number of selected targets initially included under the agreement | Item     2            
Upfront cash amount paid     $ 1,300,000            
Issued common units (in shares) | shares     1,250,000            
Non-refundable fee   $ 2,000,000 $ 500,000            
Paragon Therapeutics, Inc | Option Agreement | Maximum | Related party                  
Other Significant Agreements Paragon Option Agreement                  
Issued total common units (in shares) | shares     3,750,000            
Paragon Therapeutics, Inc | Paragon IL13 License Agreement                  
Other Significant Agreements Paragon Option Agreement                  
Expiration period of commercial sale     12 years            
Termination period of agreement     60 days            
Period of material breach     90 days            
Threshold number of days for termination upon failure to make payment and such failure persists even after the notice     30 days            
Paragon Therapeutics, Inc | Paragon IL13 License Agreement | Related party                  
Other Significant Agreements Paragon Option Agreement                  
Maximum amount of achievement of development and clinical mile stones     $ 3,000,000            
Nomination fee paid     1,000,000   $ 5,000,000 $ 2,000,000 $ 1,000,000 $ 2,000,000 $ 1,000,000
Milestone payment of trial payable     $ 2,000,000            
Paragon Therapeutics, Inc | TSLP License Agreement | Related party                  
Other Significant Agreements Paragon Option Agreement                  
Maximum amount of achievement of development and clinical mile stones $ 28,000,000                
Nomination fee paid 3,000,000       $ 3,000,000        
Milestone payment of trial payable $ 5,000,000                
[1] Includes related-party amounts of $32 for the three months ended March 31, 2025, and $6,457 for the three months ended March 31, 2024.